Venous and Arterial Thromboembolism in Lung Cancer Patients: A Retrospective Analysis

: Patients with lung cancer face an increased incidence of venous (VTE) and arterial (ATE) thromboembolism. Risk factors for thrombosis remain unclear, particularly the impact of the use of immune checkpoint inhibitors (ICIs). We sought to compare the incidence of VTE and ATE in lung cancer patients...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2024-06, Vol.13 (13), p.3773
Main Authors: Morath, Olga, Hoffmann, Julia, Schilling, Kristina, Hochhaus, Andreas, Rachow, Tobias, Lang, Susanne M
Format: Article
Language:English
Subjects:
Anticoagulants
Cancer therapies
Chemotherapy
Drug dosages
Lung cancer
Medical diagnosis
Oncology
Patients
Pulmonary embolisms
Risk factors
Thromboembolism
Thrombosis
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: Patients with lung cancer face an increased incidence of venous (VTE) and arterial (ATE) thromboembolism. Risk factors for thrombosis remain unclear, particularly the impact of the use of immune checkpoint inhibitors (ICIs). We sought to compare the incidence of VTE and ATE in lung cancer patients receiving platinum-based therapy versus those receiving ICIs alone or in combination with chemotherapy and to validate the Khorana risk score for predicting VTE in the era of ICIs. : A retrospective single-institution data analysis of 173 patients diagnosed with locally advanced or metastatic lung cancer at the Jena University hospital between 2015 and 2021. : The study revealed a high incidence of VTE (17.9%) and ATE (5.8%). The VTE risk was higher in patients diagnosed with adenocarcinoma (OR 0.29, 95% CI 0.09-0.93) than in patients with other histological types. A prior venous event was associated with an increased risk of recurrent VTE (OR 4.46, 95% CI 1.20-16.63). The incidence of thrombosis under first-line platinum-based chemotherapy did not differ from the incidence under ICIs ( = 0.19). There were no differences in the subgroup of patients who received ICIs alone or combined immunochemotherapy ( = 0.43). The Khorana score failed to predict the risk of VTE correctly. : We did not find evidence supporting the theory that ICI therapy (alone or combined) increases the risk of thrombotic events. Adenocarcinoma and a prior history of VTE were strongly associated with an increased risk of VTE. Other scores for thrombotic risk assessment in lung cancer patients should be tested in prospective studies.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm13133773